Sorafenib

Sorafenib Reactions 1704, p347 - 2 Jun 2018 Ischaemic stroke and myocardial infarction: 2 case reports In an observational retrospective study of 167 patients, two patients [ages and sexes not stated] were described, of which, one developed ischaemic stroke and the second developed myocardial infarction during treatment with sorafenib for advanced hepatocellular carcinoma (HCC) [routes, durations of treatments to reactions onsets and outcomes not stated]. The patient, who had advanced HCC, started receiving treatment with sorafenib 400mg twice daily. Subsequently, the patient developed ischaemic stroke. The patient, who had advanced HCC, started receiving treatment with sorafenib 400mg twice daily. Subsequently, the patient developed myocardial infarction. Author comment: "All patients received 800 mg/day sorafenib (400 mg twice/day) as an initial dosage." "With regards to the toxicity of treatment, the primary adverse reactions registered in the medical records . . . 1 patient suffered an ischaemic stroke . . . 1 exhibited myocardial infarction". Sanchez AIP, et al. Value of alpha-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncology Letters 15: 8863-8870, No. 6, Jun 2018. Available from: URL: http:// doi.org/10.3892/ol.2018.8400 - Spain 803324158 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Sorafenib

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/sorafenib-J7IZrVJLpV
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46990-x
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p347 - 2 Jun 2018 Ischaemic stroke and myocardial infarction: 2 case reports In an observational retrospective study of 167 patients, two patients [ages and sexes not stated] were described, of which, one developed ischaemic stroke and the second developed myocardial infarction during treatment with sorafenib for advanced hepatocellular carcinoma (HCC) [routes, durations of treatments to reactions onsets and outcomes not stated]. The patient, who had advanced HCC, started receiving treatment with sorafenib 400mg twice daily. Subsequently, the patient developed ischaemic stroke. The patient, who had advanced HCC, started receiving treatment with sorafenib 400mg twice daily. Subsequently, the patient developed myocardial infarction. Author comment: "All patients received 800 mg/day sorafenib (400 mg twice/day) as an initial dosage." "With regards to the toxicity of treatment, the primary adverse reactions registered in the medical records . . . 1 patient suffered an ischaemic stroke . . . 1 exhibited myocardial infarction". Sanchez AIP, et al. Value of alpha-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncology Letters 15: 8863-8870, No. 6, Jun 2018. Available from: URL: http:// doi.org/10.3892/ol.2018.8400 - Spain 803324158 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off